Comparative Pharmacology
Head-to-head clinical analysis: SULFISOXAZOLE DIOLAMINE versus TRYSUL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFISOXAZOLE DIOLAMINE versus TRYSUL.
SULFISOXAZOLE DIOLAMINE vs TRYSUL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfisoxazole diolamine is a sulfonamide antibiotic that competitively inhibits dihydropteroate synthase, blocking the conversion of p-aminobenzoic acid (PABA) to dihydropteroic acid, thereby inhibiting bacterial folate synthesis and nucleic acid production.
Trypanocidal agent; forms a complex with DNA and inhibits nucleic acid synthesis.
2-4 g orally initially, followed by 4-8 g/day in 4-6 divided doses for urinary tract infections; 6-8 g/day in 4-6 divided doses for nocardiosis.
2 tablets (each containing sulfamethoxazole 400 mg and trimethoprim 80 mg) orally every 12 hours for 10-14 days.
None Documented
None Documented
5-10 hours (prolonged in renal impairment; normal half-life in adults ~6 hours)
Terminal elimination half-life: 8-10 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70-100% (primarily as unchanged drug and acetylated metabolite); Biliary/Fecal: <5%
Renal: approximately 70-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: 15-20% as metabolites; small amount in feces.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic